A key limitation is the observed discrepancy between elevated PPA2 mRNA levels and reduced protein activity in AD fibroblasts, suggesting that increased mRNA reflects a compensatory mechanism rather than a direct indicator of disease pathology. This evidence concerns the gene PPA2 and Alzheimer disease.